Connect Biopharma Holdings (CNTB) EBT (2024 - 2026)

Connect Biopharma Holdings has disclosed EBT across 3 years of filings, most recently posting -$17.2 million for Q2 2026.

• In Q2 2026, EBT fell 34.1% year-over-year to -$17.2 million; the TTM figure through Jun 2026 stood at -$68.8 million (down 53.97% YoY), while the FY2025 annual figure was -$55.3 million, down 258.86% from the prior year.
• EBT came in at -$17.2 million for Q2 2026 at Connect Biopharma Holdings, up from -$19.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of $14.9 million in Q2 2024 to a low of -$19.3 million in Q1 2026.
• Average EBT over 3 years is -$10.7 million, with a median of -$12.8 million recorded in 2024.
• The largest YoY upside for EBT was 17.95% in 2025 against a maximum downside of 186.33% in 2025.
• Over 3 years, EBT stood at -$8.8 million in 2024, then tumbled by 71.39% to -$15.1 million in 2025, then dropped by 14.2% to -$17.2 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$17.2 million in Q2 2026, -$19.3 million in Q1 2026, and -$15.1 million in Q4 2025.